Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems

TH Baryakova, BH Pogostin, R Langer… - Nature Reviews Drug …, 2023 - nature.com
Poor medication adherence is a pervasive issue with considerable health and
socioeconomic consequences. Although the underlying reasons are generally understood …

Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates

BC Doak, B Over, F Giordanetto, J Kihlberg - Chemistry & biology, 2014 - cell.com
The rule of 5 (Ro5) is a set of in silico guidelines applied to drug discovery to prioritize
compounds with an increased likelihood of high oral absorption. It has been influential in …

[HTML][HTML] Capecitabine and oxaliplatin for advanced esophagogastric cancer

D Cunningham, N Starling, S Rao… - … England Journal of …, 2008 - Mass Medical Soc
Background We evaluated capecitabine (an oral fluoropyrimidine) and oxaliplatin (a
platinum compound) as alternatives to infused fluorouracil and cisplatin, respectively, for …

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation

H Gelderblom, J Verweij, K Nooter… - European journal of …, 2001 - Elsevier
Cremophor EL (CrEL) is a formulation vehicle used for various poorly-water soluble drugs,
including the anticancer agent paclitaxel (Taxol). In contrast to earlier reports, CrEL is not an …

EGFR antagonists in cancer treatment

F Ciardiello, G Tortora - New England Journal of Medicine, 2008 - Mass Medical Soc
Functional activation of growth factors and receptors of the epidermal growth factor receptor
(EGFR) family occurs in most epithelial-cell cancers, rendering EGFR a target for cancer …

Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic …

MJ Atkinson, A Sinha, SL Hass, SS Colman… - Health and quality of life …, 2004 - Springer
Background The objective of this study was to develop and psychometrically evaluate a
general measure of patients' satisfaction with medication, the Treatment Satisfaction …

Capecitabine as adjuvant treatment for stage III colon cancer

C Twelves, A Wong, MP Nowacki, M Abt… - … England Journal of …, 2005 - Mass Medical Soc
Background Intravenous bolus fluorouracil plus leucovorin is the standard adjuvant
treatment for colon cancer. The oral fluoropyrimidine capecitabine is an established …

Nanomedicine for increasing the oral bioavailability of cancer treatments

A Parodi, P Buzaeva, D Nigovora, A Baldin… - Journal of …, 2021 - Springer
Oral administration is an appealing route of delivering cancer treatments. However, the
gastrointestinal tract is characterized by specific and efficient physical, chemical, and …

Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature

D Eek, M Krohe, I Mazar, A Horsfield… - Patient preference …, 2016 - Taylor & Francis
Objective The emergence of various modes of administration for cancer treatment, including
oral administration, brings into focus the importance of patient preference for administration …

Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a …

PM Hoff, R Ansari, G Batist, J Cox, W Kocha… - Journal of Clinical …, 2001 - ascopubs.org
PURPOSE: To compare the response rate, efficacy parameters, and toxicity profile of oral
capecitabine with bolus intravenous (IV) fluorouracil plus leucovorin (5-FU/LV) as first-line …